Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer.

被引：0
|
作者：
Kalinsky, Kevin
Onishi, Maika
Yu, JiYang
Trivedi, Meghna S.
Accordino, Melissa Kate
Crew, Katherine D.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.1058
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1058
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I trial of palbociclib and paclitaxel in metastatic breast cancer.
    Clark, Amy Sanders
    O'Dwyer, Peter J.
    Heitjan, Daniel
    Lal, Priti
    Feldman, Michael D.
    Gallagher, Maryann
    Redlinger, Colleen
    Colameco, Christopher
    Lewis, David
    Zafman, Kelly
    Langer, Melissa
    Rosen, Mark Alan
    Gogineni, Keerthi
    Bradbury, Angela R.
    Domchek, Susan M.
    Fox, Kevin R.
    DeMichele, Angela
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer.
    Jameson, Gayle S.
    Borazanci, Erkut Hasan
    Babiker, Hani M.
    Poplin, Elizabeth
    Niewiarowska, Anna A.
    Gordon, Michael S.
    Barrett, Michael T.
    Ansaldo, Karen
    Lebron, Leticia
    Stoll, Amy C.
    Rosenthal, Adam
    Shemanski, Lynn R.
    Korn, Ronald Lee
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [23] Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile
    Gonzalez-Martin, Antonio
    Alba, Emilio
    Ciruelos, Eva
    Cortes, Javier
    Llombart, Antonio
    Lluch, Ana
    Andres, Raquel
    Alvarez, Isabel
    Manuel Aramenda, Jose
    Ayala de la Pena, Francisco
    Barnadas, Agusti
    Batista, Norberto
    Calvo, Lourdes
    Galve, Elena
    Garcia-Palomo, Andres
    Angel Garcia-Saenz, Jose
    de la Haba, Juan
    Lopez, Rafael
    Lopez-Vivanco, Guillermo
    Martinez-Janez, Noelia
    Martinez de Duenas, Eduardo
    Plazaola, Arrate
    Rodriguez-Lescure, Alvaro
    Ruiz, Manuel
    Sanchez-Rovira, Pedro
    Santaballa, Ana
    Angel Segui, Miguel
    Tusquets, Ignasi
    Zamora, Pilar
    Martin, Miguel
    CURRENT CANCER DRUG TARGETS, 2016, 16 (05) : 415 - 428
  • [24] Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
    Jiang, Zefei
    Ouyang, Quchang
    Sun, Tao
    Zhang, Qingyuan
    Teng, Yuee
    Cui, Jiuwei
    Wang, Haibo
    Yin, Yongmei
    Wang, Xiaojia
    Zhou, Xin
    Wang, Yongsheng
    Sun, Gang
    Wang, Jingfen
    Zhang, Lili
    Yang, Jin
    Qian, Jun
    Yan, Min
    Liu, Xinlan
    Yi, Tienan
    Cheng, Ying
    Li, Man
    Zang, Aimin
    Wang, Shusen
    Wang, Chuan
    Wu, Xinhong
    Cheng, Jing
    Li, Hui
    Lin, Ying
    Geng, Cuizhi
    Gu, Kangsheng
    Xie, Chunwei
    Xiong, Huihua
    Wu, Xiaohong
    Yang, Junlan
    Li, Qingshan
    Chen, Yiding
    Li, Fanfan
    Zhang, Anqin
    Zhang, Yongqiang
    Wu, Yudong
    Nie, Jianyun
    Liu, Qiang
    Wang, Kun
    Mo, Xueli
    Chen, Lilin
    Pan, Yueyin
    Fu, Peifen
    Zhang, Helong
    Pang, Danmei
    Sheng, Yuan
    NATURE MEDICINE, 2024, 30 (02) : 249 - 256
  • [25] A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology
    Hurria, Arti
    Soto-Perez-de-Celis, Enrique
    Blanchard, Suzette
    Burhenn, Peggy
    Yeon, Christina Haeyoung
    Yuan, Yuan
    Li, Daneng
    Katheria, Vani
    Waisman, James Ross
    Luu, Thehang H.
    Somlo, George
    Noonan, Anne M.
    Lee, Ty
    Sudan, Nimir
    Chung, Samuel
    Rotter, Arnold
    Arsenyan, Anait
    Levi, Abrahm
    Choi, Jennifer
    Rubalcava, Andrea
    Morrison, Rachel
    Mortimer, Joanne E.
    CLINICAL BREAST CANCER, 2019, 19 (02) : 89 - 96
  • [26] Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
    Zefei Jiang
    Quchang Ouyang
    Tao Sun
    Qingyuan Zhang
    Yuee Teng
    Jiuwei Cui
    Haibo Wang
    Yongmei Yin
    Xiaojia Wang
    Xin Zhou
    Yongsheng Wang
    Gang Sun
    Jingfen Wang
    Lili Zhang
    Jin Yang
    Jun Qian
    Min Yan
    Xinlan Liu
    Tienan Yi
    Ying Cheng
    Man Li
    Aimin Zang
    Shusen Wang
    Chuan Wang
    Xinhong Wu
    Jing Cheng
    Hui Li
    Ying Lin
    Cuizhi Geng
    Kangsheng Gu
    Chunwei Xie
    Huihua Xiong
    Xiaohong Wu
    Junlan Yang
    Qingshan Li
    Yiding Chen
    Fanfan Li
    Anqin Zhang
    Yongqiang Zhang
    Yudong Wu
    Jianyun Nie
    Qiang Liu
    Kun Wang
    Xueli Mo
    Lilin Chen
    Yueyin Pan
    Peifen Fu
    Helong Zhang
    Danmei Pang
    Yuan Sheng
    Nature Medicine, 2024, 30 : 249 - 256
  • [27] Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer
    Kwa, Maryann J.
    Iwano, Alyssa
    Esteva, Francisco J.
    Novik, Yelena
    Speyer, James L.
    Oratz, Ruth
    Meyers, Marleen Iva
    Axelrod, Deborah M.
    Hogan, Rebecca
    Mendoza, Sandra
    Goldberg, Judith D.
    Muggia, Franco
    Adams, Sylvia
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Concerns Regarding Phase 1b Clinical Trial of Atezolizumab Plus nab-Paclitaxel for Metastatic Breast Cancer
    Li, Juanjuan
    Wu, Qi
    Wu, Long
    JAMA ONCOLOGY, 2019, 5 (06) : 908 - 908
  • [29] Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer
    Danso, M. A.
    Blum, J. L.
    Robert, N. J.
    Krekow, L.
    Rotche, R.
    Smith, D. A.
    Richards, P.
    Anderson, T.
    Richards, D. A.
    O'Shaughnessy, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] Phase II trial of biologically optimized schedule of gemcitabine and nab-paclitaxel in metastatic pancreatic cancer
    Noonan, Anne M.
    Noonan, Anne M.
    Abushahin, Laith I.
    Wei, Lai
    Malalur, Pannaga G.
    Manne, Ashish
    Mittra, Arjun
    Roychowdhury, Sameek
    Jin, Ning
    Hays, John L.
    Babcook, Melissa A.
    Risch, Zachary
    Rahman, Shafia
    Hazard, Brooke
    Williams, Terence Marques
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345